Education
About Us
Working with TipRanks
Follow Us
Septerna, Inc. (SEPN)
NASDAQ:SEPN
SEPN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.17 - $28.99
Previous CloseN/A
Volume49.14K
Average Volume (3M)363.64K
Market Cap
$269.77M
Enterprise Value$416.13M
Total Cash (Recent Filing)$88.48M
Total Debt (Recent Filing)$12.57M
Price to Earnings (P/E)―
Beta1.85
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding44,442,497
10 Day Avg. Volume276,662
30 Day Avg. Volume363,639
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1740.82
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap1.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit387.10
Enterprise Value/Ebitda-11.80
Forecast
1Y Price Target
$19.00Price Target Upside202.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Septerna, Inc. News
PremiumCompany Announcements
Septerna, Inc. Reports 2024 Financial Results and Strategic Progress
PremiumCompany Announcements
Septerna, Inc. Shifts Focus to Next-Gen PTH1R Agonist
---
Bulls Say, Bears Say
Bulls Say
Financial PositionSepterna has approximately $421M in cash, providing sufficient financing into early 2028.
Pipeline DevelopmentSEP-631 remains on track to enter the clinic, indicating progress in the company's pipeline.
Technology PotentialSEPN is applying its Native Complex platform to build a pipeline of oral small molecule GPCR drugs, indicating significant potential for stock appreciation.
Bears Say
Catalyst UncertaintyFew stock catalysts are anticipated with the discontinuation of SEP-786's Ph1 update and an undecided future PTH candidate.
Program DiscontinuationSEP-786 was discontinued due to unexpected, off-target toxicity in 2 MAD patients, but the adverse effect was reversible and did not lead to liver injury.
Program ValueA new development candidate for the PTH program has not been selected, leading to a removal of value from the program.
---
Ownership Overview
24.41% Insiders
0.29% Mutual Funds
― Other Institutional Investors
73.30% Public Companies and
Individual Investors
SEPN FAQ
What was Septerna, Inc.’s price range in the past 12 months?
Septerna, Inc. lowest stock price was $4.17 and its highest was $28.99 in the past 12 months.
What is Septerna, Inc.’s market cap?
Septerna, Inc.’s market cap is $269.77M.
When is Septerna, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Septerna, Inc.’s earnings last quarter?
Septerna, Inc. released its earnings results on Nov 20, 2024. The company reported -$8.4 earnings per share for the quarter, missing the consensus estimate of -$5.877 by -$2.523.
Is Septerna, Inc. overvalued?
According to Wall Street analysts Septerna, Inc.’s price is currently Undervalued.
Does Septerna, Inc. pay dividends?
Septerna, Inc. does not currently pay dividends.
What is Septerna, Inc.’s EPS estimate?
Septerna, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Septerna, Inc. have?
Septerna, Inc. has 44,442,497 shares outstanding.
What happened to Septerna, Inc.’s price movement after its last earnings report?
Septerna, Inc. reported an EPS of -$8.4 in its last earnings report, missing expectations of -$5.877. Following the earnings report the stock price went up 2.443%.
Which hedge fund is a major shareholder of Septerna, Inc.?
Currently, no hedge funds are holding shares in SEPN
---
Septerna, Inc. Stock Smart Score
Company Description
Septerna, Inc.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.
---
SEPN Stock 12 Month Forecast
Average Price Target
$19.00
▲(202.07% Upside)
Technical Analysis
Vanda
―
Atea Pharmaceuticals
―
Compass Therapeutics
―
Monte Rosa Therapeutics
―
OmniAb
―
Best Analysts Covering SEPN
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-42.65%
reiterated a buy rating 22 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -42.65% per trade.
---